Cover Image

Bispecific antibody drug conjugates: Making 1+1>2

Bispecific antibody‒drug conjugates (BsADCs) represent an innovative therapeutic category amalgamating the merits of antibody‒drug conjugates (ADCs) and bispecific antibodies (BsAbs). Positioned as the next-generation ADC approach, BsADCs hold promise for ameliorating extant clinical challenges asso...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yilin Gu (Author), Zhijia Wang (Author), Yuxi Wang (Author)
Format:	Book
Published:	Elsevier, 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Antibody-drug conjugates: Recent advances in payloads
by: Zhijia Wang, et al.
Published: (2023)

Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization
by: Hui-Fang Zong, et al.
Published: (2022)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
by: Gregorio Barilà, et al.
Published: (2021)

Bispecific antibodies in cancer immunotherapy
by: Eva Dahlén, et al.
Published: (2018)

Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017)

Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody
by: Arthur J. Schick, et al.
Published: (2022)

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
by: Marlena Surowka, et al.
Published: (2021)

Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody
by: Dario A. T. Cramer, et al.
Published: (2023)

A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024)

Bispecific Antibodies Progression in Malignant Melanoma
by: Juan Tang, et al.
Published: (2022)

Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018)

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024)

Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
by: Yanze Sun, et al.
Published: (2023)

Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models
by: Feng Wang, et al.
Published: (2020)

Rational selection of building blocks for the assembly of bispecific antibodies
by: Danyang Gong, et al.
Published: (2021)

Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
by: Kristina M.J. Aertker, et al.
Published: (2024)

Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
by: Nishant Mohan, et al.
Published: (2022)

A bispecific antibody that simultaneously recognises the V2- and V3-glycan epitopes of the HIV-1 envelope glycoprotein
by: M. Davis-Gardner, et al.
Published: (2019)

Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024)

Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
by: Liang K, et al.
Published: (2021)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
by: Xinghua Pang, et al.
Published: (2023)

Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
by: William M. Pardridge
Published: (2023)

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
by: Pauline Malinge, et al.
Published: (2024)

Intein mediated high throughput screening for bispecific antibodies
by: Tim Hofmann, et al.
Published: (2020)

Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma
by: Omar Castaneda-Puglianini, et al.
Published: (2021)

CLEC5a-directed bispecific antibody for effective cellular phagocytosis
by: Vivekananda Kedage, et al.
Published: (2022)

A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties
by: Jie Zhao, et al.
Published: (2022)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
by: Daisuke Kamakura, et al.
Published: (2021)

Antibody-drug conjugates for cancer therapy
by: Anna Grzywa
Published: (2021)

Antibody-Drug Conjugates: The Last Decade
by: Nicolas Joubert, et al.
Published: (2020)

Antibody-Drug Conjugate to Treat Meningiomas
by: Kai Chen, et al.
Published: (2021)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
by: Huang L, et al.
Published: (2020)

Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
by: Johannes Schropp, et al.
Published: (2019)

Antibody-drug conjugates: Recent advances in linker chemistry
by: Zheng Su, et al.
Published: (2021)

Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
by: Xiaojing Qin, et al.
Published: (2024)

Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer
Published: (2023)

Bispecific antibody-derived molecules to target persistent HIV infection
by: Jeffrey L. Nordstrom, et al.
Published: (2022)

Bispecific antibodies: a novel approach for targeting prominent biomarkers
by: Akshita Gupta, et al.
Published: (2020)

The eIg technology to generate Ig-like bispecific antibodies
by: Lennart Kühl, et al.
Published: (2022)